News Eisai Co., Ltd.

Stocks

4523

JP3160400002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 12:00:00 09/06/2026 pm IST			5-day change	1st Jan Change
3,743.00 ^JPY	-1.66%		-1.96%	-19.68%

04/06	Eisai Co., Ltd. Announces Issuance of Unsecured Straight Bonds	CI
28/05	Jefferies Adjusts Eisai's Price Target to 4,000 Yen From 5,000 Yen, Keeps at Hold	MT

All News

Mentions Relevance

04/06	Eisai Co., Ltd. Announces Issuance of Unsecured Straight Bonds	CI
28/05	Jefferies Adjusts Eisai's Price Target to 4,000 Yen From 5,000 Yen, Keeps at Hold	MT
25/05	Eisai Co., Ltd. - Analyst/Investor Day
21/05	Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026	AQ
20/05	Eisai Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2026 (April 2026 to March 2027)	CI
15/05	Eisai Co., Ltd., 2026 Earnings Call, May 15, 2026
15/05	Eisai Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 1, 2026; Provides Dividend Guidance for Second Quarter- End and Fiscal Year Ending March 31, 2027	CI
15/05	Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2027	CI
15/05	Eisai Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
08/05	Eisai : Voluntary Recall of Distributed “Halaven®” in the Middle East and Southern Africa	PU
08/05	Eisai Co., Ltd. and Biogen Inc. Update on Fda Priority Review of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection as A Starting Dose for Early Alzheimer's Disease	CI
30/04	Eisai Posts 88 Billion Yen Leqembi Revenue For Fiscal 2025	MT
29/04	Eisai Co., Ltd. Reports Preliminary Sales Results for the First Quarter 2026	CI
22/04	Eisai, Merck's Phase 3 Kidney Cancer Drug Combo Trial Fails to Meet Survival Endpoints	MT
21/04	Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)	AQ
14/04	Jefferies Adjusts Eisai's Price Target to 5,000 Yen from 4,600 Yen, Keeps at Hold	MT
30/03	Final dividend	FA
27/03	Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy	AQ
27/03	Eisai Co., Ltd. and MSD K.K. Submit Application for Lenvima in Combination with Welireg for Renal Cell Carcinoma in Japan	CI
23/03	Eisai Present New Data on Long-Term Real-World Treatment with Lecanemab	CI
23/03	Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026	AQ
20/03	Eisai Co Ltd And Biogen Inc Announce Real-World Long-Term Treatment Persistence With Leqembi	CI
20/03	Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United States	CI
19/03	Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)	AQ
19/03	Eisai to discontinue administration of anticancer agent EZH2 inhibitor Tazverik tablets 200 mg manufactured and marketed in Japan	RE